Tetec AG   Report issue

For profit Phase 3
Founded: Reutlingen Germany (2000)
Status: Left NME R&D (2022)

Organization Overview

First Clinical Trial
2012
NCT01640457
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Tetec AG | TETEC AG Reutlingen

Active Ingredients

Drugs in Phase 3 Trials (1)

autologous culture chondrocytes (Carticel) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cartilage Diseases (Phase 3)

Fractures, Stress (Phase 3)

Intervertebral Disc Degeneration (Phase 2)

Intervertebral Disc Displacement (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 1